[Biological myolysis during combined fenofibrate-pravastatin therapy].

Jacques Raimondeau(Hôpital Laennec), J B Bouhour, Hervé Le Marec(Centre National de la Recherche Scientifique), J. C. Chevallier(Hôpital Laennec)

PubMed

April 11, 1992

Cited by 10

Related Papers

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies

|Heart Rhythm|2011|1.5k

Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death

|Nature|2003|961

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)

|EP Europace|2011|904

Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome

|Circulation|2010|850

Cardiac conduction defects associate with mutations in SCN5A

|Nature Genetics|1999|638